Shares in European automakers Volvo Cars and Stellantis surged on Thursday as stronger-than-expected U.S. sales figures alleviated investor concerns that tariffs might dampen demand. The positive performance came despite ongoing worries about higher import duties imposed by U.S. President Donald Trump as part of his administration's broader push to boost domestic manufacturing. Automakers across the industry have been implementing strategies to mitigate potential tariff impacts, including focusing on higher-margin vehicle segments.

Stellantis reported its first quarterly growth in the U.S. market this year, with new car sales rising 6% in the third quarter. The French-Italian-American automaker's shares climbed as much as 7% following the late Wednesday announcement. The company noted that all of its major brands—Jeep, Chrysler, Ram, and FIAT—experienced sales growth during the period, indicating broad-based strength across its product portfolio despite the challenging trade environment.

Volvo Cars similarly posted encouraging results, with shares rising 5% after the Swedish automaker reported a 3% increase in third-quarter U.S. sales. The company's sales composition revealed that non-electrified models continued to dominate its U.S. business, with nearly 70% of September volumes consisting of mild hybrids and other internal combustion engine vehicles. This sales mix highlights how traditional powertrains remain central to the company's American market strategy even as it expands its electric vehicle offerings.

The Swedish carmaker, majority-owned by China's Geely Holding, faces significant exposure to U.S. tariffs since most of its U.S.-bound vehicles are manufactured in Europe. Currently, Volvo produces only its electric EX90 SUV in the United States, but the company has announced plans to begin local production of its popular XC60 plug-in hybrid by the end of 2026. An additional hybrid model is scheduled for production at its South Carolina factory before 2030, representing a strategic shift toward localized manufacturing to reduce tariff vulnerability.

Nobel Prize officials in Sweden have issued a stark warning that Donald Trump's administration's cuts to scientific funding could jeopardize the United States' position as the world's leading research nation. According to officials from the Royal Swedish Academy of Sciences, the president's actions since taking office in January—including cutting billions in research funding, attacking academic freedoms, and overseeing mass layoffs of scientists across federal agencies—pose a significant threat to America's scientific dominance with potential global repercussions.

The United States currently leads all nations in Nobel science laureates, a position largely attributed to decades of sustained investment in basic science and strong academic freedoms. Hans Ellegren, secretary general of the Royal Swedish Academy of Sciences, which awards Nobel prizes in physics, chemistry, and economics, noted that "In the post-war period, the US has taken over Germany's role as the world's leading scientific nation. When they now start cutting research funding, it threatens the country's position." This assessment comes as Nobel Prize announcements approach next week in Stockholm and Oslo, where US-based researchers traditionally feature prominently among recipients.

Specific data from independent database Grant Watch reveals the scale of the funding reductions. Since January, the National Institutes of Health have terminated 2,100 research grants totaling approximately $9.5 billion, along with $2.6 billion in contracts. The affected research spans critical areas including gender studies, health effects of global warming, Alzheimer's disease, and cancer research. While efforts to restore some funding are reportedly underway, significant uncertainty persists about the long-term impact on these scientific initiatives.

The concerns extend beyond immediate funding cuts to broader implications for scientific progress. Thomas Perlmann, secretary general of the committee that awards the Nobel Prize for Medicine, emphasized that it was "no coincidence that the US has by far the most Nobel laureates," linking America's scientific success directly to its historical support for research. Additional fields facing potential impact include vaccine development, climate change research, and diversity, equity, and inclusion initiatives, raising questions about whether the current policy direction could trigger a broader scientific brain drain from American institutions.